WallStSmart

Acadia Healthcare Company Inc (ACHC)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 1722% more annual revenue ($61.37B vs $3.37B). AZN leads profitability with a 17.0% profit margin vs -33.4%. AZN appears more attractively valued with a PEG of 1.28. AZN earns a higher WallStSmart Score of 60/100 (C+).

ACHC

Hold

47

out of 100

Grade: D+

Growth: 3.3Profit: 4.0Value: 7.0Quality: 4.5
Piotroski: 4/9Altman Z: 0.29

AZN

Buy

60

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 6.7Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ACHCUndervalued (+83.0%)

Margin of Safety

+83.0%

Fair Value

$91.60

Current Price

$28.36

$63.24 discount

UndervaluedFair: $91.60Overvalued
AZNUndervalued (+18.4%)

Margin of Safety

+18.4%

Fair Value

$196.10

Current Price

$160.17

$35.93 discount

UndervaluedFair: $196.10Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACHC1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$252.33B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.8%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

Areas to Watch

ACHC4 concerns · Avg: 2.3/10
Debt/EquityHealth
1.303/10

Elevated debt levels

Return on EquityProfitability
-56.5%2/10

ROE of -56.5% — below average capital efficiency

Revenue GrowthGrowth
-0.4%2/10

Revenue declined 0.4%

EPS GrowthGrowth
-63.6%2/10

Earnings declined 63.6%

AZN2 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.5%4/10

2.5% earnings growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ACHC

The strongest argument for ACHC centers on Price/Book. PEG of 1.38 suggests the stock is reasonably priced for its growth.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.

Bear Case : ACHC

The primary concerns for ACHC are Debt/Equity, Return on Equity, Revenue Growth.

Bear Case : AZN

The primary concerns for AZN are EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

ACHC profiles as a turnaround stock while AZN is a mature play — different risk/reward profiles.

ACHC carries more volatility with a beta of 0.62 — expect wider price swings.

AZN is growing revenue faster at 6.4% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (60/100 vs 47/100), backed by strong 17.0% margins. ACHC offers better value entry with a 83.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Acadia Healthcare Company Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral health facilities to serve the behavioral health and recovery needs of the communities in the United States. United States and Puerto Rico. The company is headquartered in Franklin, Tennessee.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?